Mexico Judicial Reforms Spark Investor Concern

Mexico Judicial Reforms Spark Investor Concern

Our Chief Latin American Equity Strategist explains how potential changes in Mexico’s regulatory approach could have implications for the country’s equity markets.


----- Transcript -----


Welcome to Thoughts on the Market. I’m Nikolaj Lippmann, Morgan Stanley’s Chief Latin American Equity Strategist. Today I’ll talk about Mexico’s recent judicial reform and its potential impact on equities market.

It’s Friday, September 20, at 10am in Mexico City.

Mexico has made significant changes to its judicial system. After winning two-thirds majority in both houses – enough to allow for constitutional changes – Mexico policymakers have embarked on a robust reform agenda. Their first stop is a comprehensive reform of the judicial branch, which aims at replacing roughly 2,000 senior judges including the entire Supreme Court.

New judges will no longer be appointed but will now be elected by popular vote. This is practically unprecedented in a global context, and while the executive branch might still try to filter future candidates, this new system will likely create a real risk to checks and balances on the judicial branch as well as to expertise and procedure. Additional reforms, including the elimination of independent regulatory bodies, would likely compound these risks.

The judicial reform could have a material impact on Mexican equities. So much so, that we think Mexico goes from being an investor favorite to a ‘show me’ story where investors are less likely to give the market the benefit of the doubt. This is likely to result in a derailing or lower set of multiples being paid by investors in Mexican equities or higher risk premium required to invest.

Essentially, the judicial reforms could add fiscal, labor and concession/regulatory risk for Mexican companies, even though Mexico has deep manufacturing ecosystems, and has been well-positioned from the transition to [a] multipolar world. Just to give you a sense. Mexico has already sailed past China in terms of manufacturing exports to the United States, and are now approaching the levels of the entire European Union in terms of manufacturing export to the US.

These new reforms will raise significant investor concerns, so much so that we’ve downgraded Mexican equities to underweight, a second downgrade since June. Mexican equities have sold off roughly 20 per cent in the past three months, in dollar terms. And we think the judicial reform may contribute to further decline. All in, we see significantly greater potential for negative outcomes than positive outcomes going forward.

Looking ahead, we see three key challenges for Mexico:

First, the new judicial structure would raise concerns about the independence of the judicial branch.

Second, the United States-Mexico-Canada Agreement, the USMCA, is up for review in 2026, and Mexico's judicial reform could mean a much deeper revision. Mexico has committed to maintaining independent regulatory bodies for a number of areas, such as telecom, electricity, in competition. The judicial reform could complicate this commitment.

Electricity is a key challenge for Mexico, and it requires immediate investments. Our nearshoring investment thesis stands, but the electricity-related challenges are becoming more pronounced, and they won’t be helped by investor concerns around the judicial reform.

So all in, some businesses will be at greater risk from these developments. We expect technology, digitalization, real estate companies to be at the least level of risk, or the lowest level of risk. Domestic concessions could be at more risk.

We will continue to bring you relevant updates as Mexico reforms unfold.

Thank you for listening. If you enjoy Thoughts on the Market, please take a moment to rate and review us wherever you listen. It helps more people find the show.

Jaksot(1513)

Andrew Sheets: Four Reasons to Remain Patient

Andrew Sheets: Four Reasons to Remain Patient

Despite a needed correction in recent weeks, a suite of significant risks still hangs over U.S. markets. Chief Cross-Asset Strategist Andrew Sheets explains.

25 Syys 20202min

Michael Zezas: Unlikely Paths to Stimulus May Interest Investors

Michael Zezas: Unlikely Paths to Stimulus May Interest Investors

As hopes for an additional stimulus package wane in the run-up to the U.S. elections, some of the less likely paths to a deal may provide a way out of the current correction. Michael Zezas, Head of U.S. Public Policy Research, explains.

24 Syys 20202min

Mike Wilson: A Correction with Policy Roots

Mike Wilson: A Correction with Policy Roots

Action by Congress and the Fed, and its absence, has paved the way for the recent downturn in equities, putting markets back on a more sustainable footing. Chief Investment Officer Mike Wilson explains.

21 Syys 20203min

Andrew Sheets: The Uncertainty of the Fed’s New Certainty

Andrew Sheets: The Uncertainty of the Fed’s New Certainty

This week, the Fed announced a new framework that could keep interest rates unusually low. So why did markets collectively yawn at the announcement?

18 Syys 20203min

Special Episode: The ABCs of ESG ETFs

Special Episode: The ABCs of ESG ETFs

On this special edition of the podcast, Jessica Alsford, Head of the Global Sustainability Research Team talks with Michael Zezas about the important role ETFs are playing for ESG investing.

16 Syys 20209min

Mike Wilson: Could the Correction Continue Further?

Mike Wilson: Could the Correction Continue Further?

Why gridlock on the next U.S stimulus package—combined with election year uncertainty—suggests there could be more downside in September and October.

14 Syys 20203min

Andrew Sheets: Markets Ponder a Trillion-Dollar Question

Andrew Sheets: Markets Ponder a Trillion-Dollar Question

A downward adjustment in some high-flying U.S. tech stocks has put investors on edge this month, but an impasse on fiscal stimulus negotiations may be the real issue to watch.

11 Syys 20203min

Special Episode: Why Vaccine Discovery is Just the Beginning

Special Episode: Why Vaccine Discovery is Just the Beginning

As COVID-19 vaccine development continues in phase three studies, the logistics of FDA approvals, production and the complex hurdles of distribution are taking shape.

10 Syys 20209min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
psykopodiaa-podcast
mimmit-sijoittaa
rss-rahapodi
herrasmieshakkerit
lakicast
rss-rahamania
ostan-asuntoja-podcast
rss-neuvottelija-sami-miettinen
rss-startup-ministerio
rss-lahtijat
oppimisen-psykologia
pari-sanaa-lastensuojelusta
taloudellinen-mielenrauha
leadcast
syo-nuku-saasta
rahapuhetta
rss-myyntipodi
rss-bisnesta-bebeja
rss-karon-grilli